Clinical Trials Logo

Toxic Epidermal Necrolysis clinical trials

View clinical trials related to Toxic Epidermal Necrolysis.

Filter by:
  • None
  • Page 1

NCT ID: NCT06119490 Recruiting - Clinical trials for Toxic Epidermal Necrolysis

Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis

TEN
Start date: July 5, 2023
Phase: Early Phase 1
Study type: Interventional

To evaluate the efficacy and safety of methylprednisolone combined with the JAK inhibitor abxitinib and tofacitinib in the treatment of toxic epidermal necrolysis

NCT ID: NCT04711200 Not yet recruiting - Clinical trials for Mesenchymal Stromal Cells

LYell SYndrome MEsenchymal Stromal Cells Treatment

LYSYME
Start date: September 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare severe cutaneous adverse reactions (SCARs) to drugs. To date, no curative drug has demonstrated with a good level of evidence its ability to promote SJS and TEN healing and could contribute to earlier reepithelialisation. Mesenchymal stroma cells (MSCs) therapy represents a new therapeutic approach. eg, in patients with cardiovascular diseases, neurological diseases, renal transplantation, lung diseases as acute respiratory distress syndrome. Recently, MSCs have been proposed in both burn wound healing with a significantly decrease of the unhealed burn area and in cutaneous radiation. Moreover, MSCs have immunomodulation properties potentially effective in refractory acute and chronic graft versus host disease (GVHD) by improving thymic function and induction of Tregs. Indeed, MSCs are able to migrate to inflamed tissues after stimulation by pro-inflammatory cytokines and to modulate the local inflammatory reactions. MSCs have also demonstrated their ability to promote tissue remodelling, angiogenesis and immunomodulation through either differentiation or secretion of several growth factors such as VEGF, basic FGF and various cytokines. Therefore, combining their immunomodulation effect and secretion of soluble factors involved in wound repair, MSCs might be valuable as a cell therapy strategy for promoting cutaneous healing in SJS-TEN syndrome and subsequently decrease the morbi-mortality.

NCT ID: NCT03585946 Not yet recruiting - Clinical trials for Stevens-Johnson Syndrome

Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis

Start date: January 1, 2024
Phase:
Study type: Observational

This is a prospective, multicenter cohort observational; study to compare treatment outcomes in patients admitted to the hospital with Stevens-Johnsons Syndrome/Toxic Epidermolysis, aiming to assess the utility of medical management. The hypothesis of this study is that one or more treatment options will demonstrate improved patient outcomes. The primary objectives are cessation of progression of disease, time to complete re-epithelialization, length of stay, and mortality rate in the treatment groups as compared to those receiving supportive care alone. Exploratory analyses will assess the cause, risk factors, and severity prediction factors associated with the disease.

NCT ID: NCT02795143 Withdrawn - Clinical trials for Toxic Epidermal Necrolysis

Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study

Start date: November 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether isotretinoin is helpful in treating patients with an adverse cutaneous drug eruption known as toxic epidermal necrolysis (TEN).

NCT ID: NCT02574988 Recruiting - Clinical trials for Toxic Epidermal Necrolysis

Severe Cutaneous Adverse Reactions in Thailand

ThaiSCAR
Start date: January 2014
Phase:
Study type: Observational [Patient Registry]

The multicenter registry of patients with severe cutaneous adverse reactions among tertiary medical institutes in Thailand to study clinical characteristics, etiologies, therapeutic outcomes, quality of life, and the values of in vitro drug allergy diagnosis for the confirmation of the causative drugs

NCT ID: NCT02319616 Withdrawn - Clinical trials for Toxic Epidermal Necrolysis

Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis

TEN
Start date: November 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objectives of this study are to investigate the efficacy and safety of topical steroid ointment (clobetasol 0.05%) for the treatment of the cutaneous manifestations of toxic epidermal necrolysis (TEN).

NCT ID: NCT02037347 Terminated - Clinical trials for Stevens-Johnson Syndrome

Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis

Start date: October 2010
Phase: Phase 1/Phase 2
Study type: Interventional

To test the ability of palifermin (a recombinant human keratinocyte growth factor) to decrease mucocutaneous injury and to promote epithelial repair in Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis Overlap, diseases in which there is extensive sloughing of the skin and mucosa, including that of the eyes, gastrointestinal tract, respiratory and genitourinary systems.

NCT ID: NCT01696500 Completed - Clinical trials for Stevens-Johnson Syndrome

Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.

Start date: October 2012
Phase: Phase 3
Study type: Interventional

Patients diagnosed with Stevens-Johnson syndrome and Toxic Epidermal Necrolysis were confirmed based on the investigators national diagnostic criteria. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days. Subsequently, efficacy of NPB-01 for therapy of Stevens-Johnson syndrome and Toxic Epidermal Necrolysis will be evaluated the disease evaluation score et al. As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse events by 20 days after the start of the study treatment.

NCT ID: NCT00372723 Withdrawn - Clinical trials for Toxic Epidermal Necrolysis

Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)

Start date: July 2006
Phase: Phase 2
Study type: Interventional

To determine whether treatment of patients who have toxic epidermal necrolysis with a drug called remicaide increases the number of patients who are alive 30 days laters.